Dendritic cells (DC) are essential for the development and regulation of adaptive host immune responses against tumors. DC are heterogeneous and comprised of diverse cellular subsets. They are best known for mediating a crucial role in the initiation of acquired immunity by serving as professional antigen presenting cells (APC) that take up antigens in their local microenvironment, which are then processed and presented to naïve T cells in the context of major histocompatibility complex (MHC) class I and II molecules. In addition to these functions, DC can modulate the types of T cell responses they generate, and can also influence the responses of innate effectors, such as NK cells. There is also now evidence that they may mediate a more primordial role as innate, effector cells that are tumoricidal. 'Killer' DC (KDC) may represent a true 'multi-tasking' cell type that can sequentially act as a 'hunter-gatherer' of antigens; as well as, an instructor, then enforcer/regulator, of antigenspecific anti-tumor T-cell responses in vivo. In this review, we will critically examine the published record regarding KDC, their mechanism(s) of action, and then consider the potential integration of KDC into novel immunotherapies for patients with cancer.
Subsets of Natural and Induced KDC
Killer DC (KDC) have been described in both rodents and humans, with the ability of DC to directly mediate cellular cytotoxicity first reported by Suss et al. 1 for the CD8a þ subset of murine splenic DC, where these cells were found competent to induce the apoptotic death of allogeneic T cells through a Fas/Fas ligand-dependent mechanism. 1 While it has been also suggested that the induction of T-cell apoptosis by CD8a
þ DC may represent a mechanism for maintaining peripheral T-cell tolerance in the mouse, this conclusion is clearly controversial, as CD8a þ DC can also effectively initiate T-cell responses both in vitro and in vivo. 2, 3 Nevertheless, subsequent evaluations indicated that murine bone marrow (BM)-derived DC (BM-DC) were capable of mediating the Fas-dependent apoptosis of a human transformed T cell line (i.e. Jurkat). 4 These initial findings that DC could promote the apoptotic death of primary and transformed T cells (under at least some conditions) served as fuel for subsequent investigations of the comparative ability of DC subpopulations to serve as KDC against tumor cells (Table 1) .
One of the first published studies detailing the cytotoxic properties of human DC compared the tumoricidal functions of freshly-isolated, peripheral blood, CD11c þ DC and pre-DC (CD11c À IL-3Ra þ ). 18 Following treatment with IFN-a or IFN-g, CD11c þ DC, but not IL-3Ra þ pre-DC, expressed detectable levels of cell surface tumor necrosis factor-related apoptosisinducing ligand (TRAIL) and were able to instigate TRAILdependent apoptosis of a range of human tumor cell lines (Table 2) . Another early report suggested that HLA-DR þ , lineage À DC isolated from peripheral blood express detectable levels of TNF family members associated with the ability to mediate apoptosis, such as tumor necrosis factor (TNF), TRAIL, FasL, Lymphotoxin (LT)-a, LT-b on their cell surface. 22 However, these DC were not directly assessed for their cytolytic reactivity against tumor cells. In more recent studies, freshly-isolated, myeloid-type M-DC8 þ DC (pre-treated with IFN-g) from the peripheral blood have been shown to promote target cell apoptosis via a mechanism that is at least partially TNF-a-dependent. 19 Interestingly, within the M-DC8 þ blood DC population, the Fc receptor (CD16 and CD32)
þ subpopulation of KDC, appears capable of mediating antibodycoated target cell death via antibody-dependent cellular cytotoxicity. 20 In addition to promoting tumor cell death via apoptotic mechanisms, KDC may also inflict necrotic cell death on tumor cells. Thus, human HLA-DR þ , CD11c þ peripheral blood-derived myeloid DC (in the presence of toll-like receptor (TLR)-7/8 ligand agonists) express perforin and granzyme B, and serve as potent KDC against the chronic myelogenous leukemia cell line K562, but not the Jurkat T cell line (known to be refractory to perforin/granzyme-mediated death). 21 Curiously, while human plasmacytoid DC (pDC) express intracellular granzyme B constitutively, TLR7 ligand engagement on pDC results in the ability of these cells to mediate apoptosis of Jurkat cells via a TRAIL-dependent mechanism, but not K562 cells which are resistant to TRAIL-induced apoptosis. 21 These findings suggest that freshly-isolated human DC subsets isolated from the peripheral blood require some form of activation (i.e pro-inflammatory signals provided by IFNs, TLR ligands, among others) to upregulate effector molecule expression associated with optimal anti-tumor KDC function implementing the apoptotic and/or necrotic pathways. This dependency on activation for KDC functionality may serve as a safe-guard against untoward cytotoxicity directed against normal or immunologically-beneficial (i.e. effector/memory T cells).
Natural KDC have also been identified in mice; and similar to human DC, the pre-activation of DC is generally required for these cells to mediate cytotoxicity against target cells (Table 1) . For instance, in mice, epidermal Langerhans cells are known to upregulate their cell-surface expression of FasL after activation with CD40 ligand, resulting in their ability to kill Jurkat cells via apoptosis. 5 We were unable to identify any published reports of tumor killing induced by conventional myeloid DC (mDC;
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Hence, it remains unclear whether these DC subsets exhibit this property spontaneously, or if they must be induced to acquire it.
On the other hand, a novel murine subset of splenic DC was recently identified, and coined 'natural killer DC' (NKDC). 14, 15 These cells have overlapping characteristics of both cytolytic effector cells and professional antigen presenting cells (APC) (i.e. they possess phenotypic and functional properties consistent with NK cells and DC; see review by Spits and Lanier 26 ). NKDC undergo rapid expansion in vivo during lymphocytic choriomeningitis virus (LCMV) infection and secrete IFN-g. 14 A subset of the heterogeneous NKDC population has been described as interferon-producing killer DC (IKDC) 16, 17 (recently reviewed in Shortman and Villadangos 27 ), recognized on the basis of a CD11c
À phenotype. These cells secrete IFNs and have NK-like cytotoxicity (dependent in part upon NKG2D) in addition to APC function. 17 IKDC cells do not spontaneously express major histocompatibility complex (MHC) Class II, but 16, 29, 30 IFNs may mediate a feedback loop, resulting in the upregulation of TRAIL by these DC, which is required for the observed killing of NK-resistant targets by IKDC. In contrast, CpG ODNs appear to promote NKG2D-dependent cytotoxicity of NKsensitive targets (as well as RAE1 þ transfectants) by IKDC. A true counterpart to the murine NKDC/IKDC population has yet to be identified in humans; however, an IL-18-induced NK subpopulation that coexpresses at least some DC markers (i.e. CD83) has been described. 31 Further, there is evidence supporting the instructive crosstalk between NK and DC, 32 that could spawn such tumoricidal KDC.
In rats, a DC subset identified in freshly isolated spleen or lymph nodes (bearing a CD4
þ phenotype) has been reported to promote the apoptotic death of NK-sensitive and NK-resistant tumor cell lines, but not T cells. 6, 7 Unexpectedly, the underlying mechanism of cytotoxicity appears independent of Fas/FasL, TRAIL, TNF and caspase, 6, 7 and is ablated upon DC maturation. Notably, following the apoptosis of tumors, KDC were observed to ingest dying 5-(and -6)-carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled target cells as assessed by flow cytometry and confocal microscopy, 7 providing a potential substrate for specific T-cell stimulation. An independent group has similarly reported that rat CD103 þ KDC may be activated via NKR-P2 signaling (the rat ortholog of mouse NKG2D), with an agonist antibody against NKR-P2 demonstrated to augment KDC tumoricidal function in vitro and to delay tumor growth in vivo. 8, 9 In contrast to prior studies performed on human and mouse KDC, these rat KDC mediate tumor cell death through a mechanism dependent upon nitric oxide (NO) production. 9 This does not rule out the possibility that additional pathways may be coutilized for optimal KDC function, or that additional activating factors/conditions may induce rat KDC to acquire TNF-family member-or perforin/ granzyme-dependent mechanisms for promoting tumor cell death. Indeed, the NO-dependency of KDC lysis observed by Srivastava et al. 9 may reflect the reported ability of NO to sensitize tumor cell targets to apoptosis mediated by KDC via Fas, etc. 13 
Cultured KDC Generated from Bone Marrow Progenitor Cells or Monocytes
Due to the logistical limitations imposed by the relative rarity of DC subpopulations in vivo, many have turned to analyses of DC generated from precursor populations in vitro. Despite the obvious caveats associated with the physiologic relevance of a given cultured DC population, these cells can be produced in large numbers for modeling purposes and may represent a platform for the development of therapeutic DC-based vaccines and therapies for cancer patients.
Studies of BM-DC in rodents have given further insights into the killing properties of DC. Interestingly, it appears that such in vitro generated DC exhibit most potent cytotoxic potential after undergoing 'spontaneous' maturation (occurring over time in the absence of known exogenous activators). 13 TNF family members including FasL, TRAIL and TNF-a are expressed by cultured immature and spontaneously-matured BM-DC, 4,13 allowing these KDC to promote the apoptosis of human Jurkat cells and the murine A20 B cell lymphoma, with Fas-L (-/-) DC proving inferior in KDC function. 13 Furthermore, transduction of BM-DC with adenovirus constructs encoding mIL-12p70 and mIL-18 leads to enhanced TNF-a and TRAIL expression and improved KDC function against syngenic CMS4 sarcoma cells. 12 As previously mentioned, NO appears to represent yet another lytic agent, or (at least) a sensitizer of tumor cells to cytotoxicity mediated by both rodent KDC. 9, 10, 11, 13 Human DC generated in vitro from monocyte (mono-DC) precursors have also been reported to kill various tumor cell lines in the absence of overt exogenous stimuli (Table 3) . 19, 22, 33, 34, 36 The specific mechanism(s) by which these DC promote the demise of tumor cells remains highly controversial, with numerous examples of directly conflicting reports. For example, Vanderheyde et al. 33 reported that mono-DC killing occurred independently of DC expressed TNF, FasL or TRAIL, since specific blocking antibodies or soluble fusion proteins did not antagonize the ability of these cells to induce tumor cell apoptosis. However, Lu et al. 22 reported that all three of these TNF-family members, in addition to LT-a and LT-b, are responsible for the observed cumulative tumoricidal activity exhibited by DC (i.e. specific, single antagonists for each TNF family member molecule provided only incremental inhibition of KDC activity, while the combined use of all inhibitors effectively ablated DC-mediated killing).
In general, the cytolytic capacity of cultured human mono-DC is enhanced by certain activation stimuli, although these need not represent conventional maturation factors. 36 Crosslinking of CD40 molecules (using rhCD40L) expressed by DC enhances the ability of these APC to inhibit the growth of tumor cell lines via a (TNF-a-dependent) apoptotic mechanism in coculture experiments. 37, 38 As a cautionary note, however, a number of carcinomas (cell lines and tissue specimens) may themselves express CD40, and the growth and survival of these tumor cell lines can be inhibited directly by rhCD40L. 44, 45 This may suggest that at least some of the KDC anti-tumor effects observed by Joo et al. 37 may be KDC-independent. 42 This is consistent with analyses of freshly-isolated human DC subsets, where FasL does not appear to play a significant role in tumor cell killing. Equivocal data also exists for the role of TRAIL in human DC-mediated killing. For instance, TRAIL expression has been reported to be readily upregulated on mono-DC using TLR ligands (i.e. doublestranded RNA or LPS) or IFN-b, in association with improved KDC function. However, this has only been observed in some, 38, 39 but not all investigations. 33 Ex vivo DC generated from sources other than peripheral blood monocytes have also been reported to promote the apoptosis of tumor cells. Ascitic monocytes from ovarian cancer patients that are cultured to become mono-DC acquire the ability to kill both autologous and allogeneic ovarian carcinoma cell lines in vitro via a FasL-dependent mechanism. 41 Cord blood-derived mono-DC stimulated with IFN-g can kill the Jurkat (T lymphoma) and HL-60 (myelomonocytic leukemia) tumor cell lines, but not Daudi (Burkitt's lymphoma), tumor cell lines. However, when stimulated with LPS, these DC kill the Daudi and Jurkat, but not the HL-60, target cells. 40 Both treatments appear to upregulate DC expression of intracellular TRAIL with little effect on TNF or FasL, although the functional role of these TNF family members in tumor cell killing by DC was not investigated. CD34
þ progenitor cellderived DC express TRAIL, which can be enhanced by both LPS and IFN-b, and play an, at least, partial role in the DCinduced apoptotic death of hematopoietic tumor cell lines. 39 At present, it is not clear why a relatively homogenous population such as mono-DC (generated under a standardized culture protocol using rhGM-CSF and rhIL-4 from peripheral blood mononuclear cells) exhibits such diversity with regard to constitutive or induced ability to kill tumor cells and the relevant underlying mechanisms involved in their KDC effector function. However, there appears to be a general consensus that ex vivo generated DC can kill tumor cells in vitro, similar to findings reported for fresh isolates of human DC. Like murine BM-DC, multiple, concerted mechanisms appear to be employed by human mono-DC to initiate tumor cell death (although there have not yet been any reports supporting a role for NO in tumor cell killing by human DC). Interestingly, cultured murine and human DC appear competent to kill tumor cells in the absence of additional activating signals, in contrast to their in vivo counterparts. This may suggest that KDC function is tightly-regulated in vivo.
DC-Mediated Tumoricidal Activity In Vivo
The evidence for physiological relevance of DC cytotoxicity in vivo remains somewhat circumstantial. In patients undergoing treatment for basal cell carcinoma with the TLR7 agonist Imiquimod, both mDC and pDC appear to colocalize near dead/dying tumor cells in situ. 21 Both tumor-infiltrating DC (TIDC) subsets express granzyme B and TRAIL within lesions, and myeloid DC additionally express perforin, TNF and inducible NO synthase (iNOS; with only trace levels of FasL detected). 21 This suggests that human TIDC, when activated appropriately, may contribute to tumor cell death (and the consequent cross-priming of anti-tumor T cells in tumor-draining lymph nodes), although direct proof has not yet been provided. While the demonstration of direct DCmediated killing of tumor cells in vivo is a technically daunting agenda, intra-tumoral injection of DC or treatment of tumors with DC-activating factors has been shown to correlate with reduced tumor growth and even regression. 9, 10, 12, 21, 35, 46 Clearly such anti-tumor activity could prove the result of KDC activity, but it could equally well involve DC-induced tumoristatic/antiangiogenic properties 34, 43 and/or the ability of lesion associated DC to activate effector NK and T cells that could themselves mediate tumor cell death. 32 Studies of DCmediated tumor apoptosis in T/NK-deficient hosts could prove instrumental in visualizing direct killing of tumor cells in situ by DC; although it is likely that tumor regression would not be observed under these conditions, since both T and NK would likely be required for complete tumor eradication. This does not diminish the potential importance of KDC activity in the afferent aspects of anti-tumor immunity (i.e. improved crosspriming of tumor-specific T cells).
Crosspriming of Anti-Tumor Immunity by KDC
DC can acquire tumor antigens through a range of uptake mechanisms including fluid-phase or receptor-mediated uptake of soluble antigens released from necrotic tumor cells, 47 active piracy of living tumor cell membrane components, 48 as well as, by phagocytosis and receptor-mediated internalization of apoptotic tumor bodies and necrotic tumor debris. 49 All of these mechanisms provide DC with tumor antigen substrates that may be processed and presented in the context of MHC molecules for recognition by cognate T cells in the tumor-bearing host (Figure 1) . Indeed, there is preclinical evidence that subsequent to DC-mediated lysis of target cells, these APC engulf antigens from tumor apoptotic bodies, enabling them to cross-prime T-cell responses. 7, 13, 41 Therapeutic Implications for KDC While formal proof is lacking, if the same cell that kills the tumor takes up the apoptotic body and presents its derivative antigens to T cells in secondary lymphoid organs, the potential convergence of these varied functions in KDC would yield a physiologically-economical/efficient anti-tumor paradigm attractive for clinical translation in the cancer setting. In the context of such a paradigm, two major forms of KDC clinical trials could be immediately envisioned: 1) approaches utilizing ex vivo generated KDC injected into accessible tumor lesions or that would predictably home into tumor lesions after systemic administration; or 2) treatment of cancer patients with modalities that augment KDC function in vivo, particularly within the tumor microenvironment. Each of these strategies could be combined with additional modalities that sensitize tumors to KDC-mediated cell death and/or sustain KDC function within the hostile confines of cancer lesion.
The consideration of developing 'super'-KDC ex vivo for intra-tumoral administration is made more attractive by reports of site-specific tumor regression in patients with metastatic breast cancer or melanoma after injection of autologous (FasL þ , IFN-a þ ) DC into tumor lesions. 46 The overexpression of TNF-family members by adenoviral transduction 42 or modulators known to at least transiently increase the expression of these molecules on human DC could yield improved KDC with greater clinical efficacy. Still, the inability of adoptively transferred DC to mediate distal tumor shrinkage, even in cases where the primary lesion (into which DC were injected) exhibits resolution, suggests that additional biological response modifiers may need to be integrated into combinational approaches to fortify and sustain tumorspecific immunity that may be prompted by KDC in vivo.
Therapies designed to promote the infiltration of tumor lesions by KDC to mediate the 'immunogenic death' of tumor cells is logistically more attractive than ex vivo approaches for clinical implementation. Support for the potential success of this strategy may be suggested by current clinical trials implementing the TLR7 ligand, Imiquimod, for the treatment of cutaneous basal cell carcinoma. This therapy enhances DC recruitment into tumor lesions, and increases tumor apoptosis in situ, possibly through the in vivo activation of KDC. 21 In addition, NKDC/IKDC have been shown to cause tumor regression in vivo. Therapeutic responses mediated by Gleevec and IL-2 in the B16F10 experimental model of melanoma metastasis have been shown to involve TRAIL expressed on IKDC. 16, 35 Similarly, CpG þ IL-18 treatment to prevent B16-F10 lung metastases appears to be mediated by NKDC, 29 as the depletion of these cells eliminates therapeutic efficacy, while the adoptive transfer of CpG þ IL-18 activated NKDC protects against lung metastases. Flt-3 ligand and GM-CSF have been used to expand systemic DC populations in both humans and mice. However, in mice, IKDC are preferentially expanded in vivo by CpG, 15, 17 Flt-3 ligand 50 (or during viral infection 14 ). In the event that a human equivalent of murine NKDC/IKDC is identified, factors supporting their expansion and sustained functionality in vivo should receive considerable clinical attention.
With regard to sensitizing tumors to KDC-mediated killing in situ, as a means to improve the efficacy of either ex vivo or in vivo KDC therapy approaches, we have recently shown that NO pretreatment of tumors enhances their sensitivity to DCmediated cytotoxicity involving multiple TNF family members (i.e. including TRAIL, TNF-a and FasL). 13 NO itself did not directly promote tumor cell death, but rather reduced the expression of an anti-apoptotic protein (i.e. survivin) in treated tumor cells, 13 making them more prone to KDC-induced apoptosis. Application of alternate pre-sensitizers including chemotherapy, radiotherapy or gene therapy (to promote the specific knockdown of anti-apoptotic proteins in tumor cells) could dramatically improve the (systemic rather than locoregional) clinical benefits associated with KDC-based therapies.
Finally, one could consider therapy modifications that would result in sustained KDC survival (i.e. making them more resistant to self-inflicted or tumor-induced apoptosis) 42, 51, 52 and functionality (i.e. preventing tumor-induced deviation/ suppression) in cancer patients. Coadministration of TLR agonists (i.e. Imiquimod, CpG ODN), CD40 ligand or cytokines, such as IL-12p70, may not only enhance DC survival, [51] [52] [53] [54] but coordinately bolster KDC cytolytic potential.
Conclusions and Future Directions
In addition to their pre-eminent role as a master regulator of adaptive immunity mediated via their APC functions, 55 DC may exert a more primitive, innate immune effector cell function, namely the ability to kill aberrant (tumor) cells. Consistent with the 'plasticity' associated with DC differentiation potential, KDC appear competent to promote tumor cell death via a broad array of killing mechanisms, including those linked to apoptotic and necrotic death. Current opinions diverge with regard to which mechanism(s) may be more dominant for a given DC subpopulation or for DC conditioned in specific ways (i.e. in inflammatory or tumor-microenvironmental states). Such controversy may merely suggest that DC employ multiple, coordinate mechanisms (i.e. TNF family members, grazyme/perforin, NO) to induce tumor cell death. Under such conditions, pleiotropy in KDC mechanisms of action provide a safe-guard against evolving, progressor tumor lesions containing a population of cells that are heterogeneous with regard to their sensitivity to the various death pathways. Clearly, the ability of KDC (delivered into the tumor microenvironment via adoptive transfer or by the conditioning or recruitment of endogenous cells into cancer lesions in vivo) to generate an antigenic substrate that they are competent to then uptake and process into MHCpresented epitopes, is logistically attractive in the development of afferent anti-tumor immunity and/or the potentiation of efferent immunity within the tumor microenvironment. Based on the complex and often dysfunctional immunobiology of cancer-bearing hosts, however, the translational integration of KDC in prospective immunotherapies will likely require the development of combinational approaches. Such strategies should consider concomitant means to increase tumor cell sensitivity to KDC, to modulate the functional polarization of KDC-induced immunity and/or to extend effector KDC and T-cell functionality in vivo.
